Obesity
📧 Sign up to get email alerts when something new happens for Obesity.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-05-07FDA Approved: CONTRAVE EXTENDED-RELEASE — Supplemental Application (Nalpropion Pharmaceuticals LLC)
FDA approved a supplemental application for CONTRAVE EXTENDED-RELEASE (naltrexone hydrochloride and bupropion hydrochloride) submitted by Na…
-
FDA approval · 2024-04-18FDA Approved: METHAMPHETAMINE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for methamphetamine hydrochloride (Hikma Pharmaceuticals USA Inc.).
-
FDA approval · 2024-03-08FDA Approved: WEGOVY — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for Wegovy (semaglutide) from Novo Nordisk to enhance its labeling for weight-management use.
-
FDA approval · 2024-02-07FDA Approved: METHAMPHETAMINE HYDROCHLORIDE — Supplemental Application (Mayne Pharma Commercial LLC)
FDA approved a supplemental application for methamphetamine hydrochloride (Mayne Pharma Commercial LLC).
-
FDA approval · 2024-02-06FDA Approved: PHENTERMINE AND TOPIRAMATE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application from Prasco Laboratories for phentermine and topiramate, a weight-management combination therapy…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-11-30FDA Approved: CONTRAVE EXTENDED-RELEASE — Supplemental Application (Nalpropion Pharmaceuticals LLC)
FDA approved a supplemental application to authorize an extended-release formulation of CONTRAVE (naltrexone hydrochloride and bupropion hyd…
-
FDA approval · 2023-11-15FDA Approved: IMCIVREE — Supplemental Application (Rhythm Pharmaceuticals, Inc)
The FDA approved a supplemental application for IMCIVREE (setmelanotide) submitted by Rhythm Pharmaceuticals, Inc.
-
FDA approval · 2023-11-08FDA Approved: ZEPBOUND — Original Application (Eli Lilly and Company)
The FDA approved ZEPBOUND (tirzepatide) from Eli Lilly through an original application for obesity/weight management in adults. This marks t…
-
FDA approval · 2023-07-21FDA Approved: WEGOVY — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for Wegovy (semaglutide) submitted by Novo Nordisk to update its label.
-
FDA approval · 2023-06-28FDA Approved: PHENTERMINE AND TOPIRAMATE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application from Prasco Laboratories for phentermine and topiramate, enabling a generic version of the obesity w…
-
EMA approval · 2023-05-10EMA Authorised: Xenical (orlistat) — CHEPLAPHARM Arzneimittel GmbH
European Medicines Agency authorises Xenical (orlistat) for obesity through CHEPLAPHARM Arzneimittel GmbH.
-
FDA approval · 2023-05-09FDA Approved: PHENTERMINE AND TOPIRAMATE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application from Prasco Laboratories for phentermine and topiramate, a weight-management medication. This action…
-
FDA approval · 2023-04-20FDA Approved: SAXENDA — Supplemental Application (Novo Nordisk)
The FDA approves a supplemental application for SAXENDA (liraglutide) submitted by Novo Nordisk.
-
FDA approval · 2022-12-23FDA Approved: WEGOVY — Supplemental Application (Novo Nordisk)
The FDA approved Novo Nordisk's supplemental application for Wegovy (semaglutide).
-
FDA approval · 2022-11-17FDA Approved: XENICAL — Supplemental Application (H2-Pharma LLC)
The FDA approved a supplemental application for Xenical (orlistat) submitted by H2-Pharma LLC.
-
FDA approval · 2022-08-24FDA Approved: WEGOVY — Supplemental Application (Novo Nordisk)
The FDA approved Novo Nordisk's supplemental application for Wegovy (semaglutide). This action expands its labeling to support chronic weigh…
-
FDA approval · 2022-06-24FDA Approved: PHENTERMINE AND TOPIRAMATE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application from Prasco Laboratories for the combination drug phentermine/topiramate.
-
FDA approval · 2022-06-15FDA Approved: SAXENDA — Supplemental Application (Novo Nordisk)
FDA approved Novo Nordisk's supplemental application for SAXENDA (liraglutide), finalizing an updated labeling to support weight-management …
-
FDA approval · 2022-03-08FDA Approved: PHENTERMINE AND TOPIRAMATE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for phentermine and topiramate from Prasco Laboratories.
-
FDA approval · 2021-06-04FDA Approved: WEGOVY — Original Application (Novo Nordisk)
The FDA approved Wegovy (semaglutide) in an original application for chronic weight management in adults with obesity or overweight with wei…
-
FDA approval · 2021-03-31FDA Approved: PHENTERMINE AND TOPIRAMATE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for phentermine and topiramate submitted by Prasco Laboratories.
-
FDA approval · 2021-01-06FDA Approved: BENZPHETAMINE HYDROCHLORIDE — Supplemental Application (Epic Pharma, LLC)
The FDA approved a supplemental application for benzphetamine hydrochloride developed by Epic Pharma, LLC.
-
FDA approval · 2021-01-05FDA Approved: BENZPHETAMINE HYDROCHLORIDE — Supplemental Application (KVK-TECH, INC)
FDA approved a supplemental application for benzphetamine hydrochloride from KVK-Tech, Inc. This action confirms the drug's regulatory appro…
-
FDA approval · 2020-12-04FDA Approved: SAXENDA — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for SAXENDA (liraglutide) from Novo Nordisk.
-
FDA approval · 2020-11-13FDA Approved: PHENDIMETRAZINE TARTRATE — Supplemental Application (Acertis Pharmaceuticals, LLC)
FDA approved a supplemental application for phendimetrazine tartrate from Acertis Pharmaceuticals, LLC.